Hepatocellular Carcinoma after Treatment of Cirrhotic Hepatitis C Virus Patients with Direct Acting Antiviral Treatment

Earlier treatment plans based on the use of interferon (IFN) were characterised by a sustained virological response (SVR) of 40–50%., but Since direct acting anti viral therapy (DAAs) introduced to treat chronic hepatitis (C) patients , result in interesting high rate of sustained virologic response by 95% with a good safety profile with reduction in death rate as well as hepatocellular carcinoma (HCC) ,despite this high rate of SVR the risk of (HCC) doesn't eliminated , data puplished in 2016 were a source of worry regarding the (HCC) appear post treatment either de novo or recurrence , in addition tumour characteristic after DAAs more aggressive , Discovered that following DAAs tumours displayed aggressive behaviour, had a larger number of nodules, and had extrahepatic metastases, demonstrating that cancer growth is faster than expected in these patients, this is because The use of powerful IFN-free DAAs treatments may result in rapid viral suppression and reduce inflammatory cytokine responses .